KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short-Term Debt issuances (2017 - 2025)

Amneal Pharmaceuticals has reported Short-Term Debt issuances over the past 7 years, most recently at $218.0 million for Q1 2025.

  • Quarterly results put Short-Term Debt issuances at $218.0 million for Q1 2025, up 354.17% from a year ago — trailing twelve months through Dec 2025 was $218.0 million (up 354.17% YoY), and the annual figure for FY2025 was $218.0 million, up 354.17%.
  • Short-Term Debt issuances for Q1 2025 was $218.0 million at Amneal Pharmaceuticals, up from $48.0 million in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for AMRX hit a ceiling of $218.0 million in Q1 2025 and a floor of $10.0 million in Q3 2023.
  • Median Short-Term Debt issuances over the past 4 years was $80.0 million (2023), compared with a mean of $81.4 million.
  • Biggest five-year swings in Short-Term Debt issuances: tumbled 76.47% in 2023 and later skyrocketed 354.17% in 2025.
  • Amneal Pharmaceuticals' Short-Term Debt issuances stood at $85.0 million in 2022, then grew by 28.24% to $109.0 million in 2023, then crashed by 55.96% to $48.0 million in 2024, then skyrocketed by 354.17% to $218.0 million in 2025.
  • The last three reported values for Short-Term Debt issuances were $218.0 million (Q1 2025), $48.0 million (Q1 2024), and $109.0 million (Q4 2023) per Business Quant data.